Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nasal disorders and anticholinergic therapy.

P Borum1

  • 1Department of Otorhinolaryngology, Rigshospitalet DK-2100, Copenhagen, Denmark.

Postgraduate Medical Journal
|January 1, 1987
PubMed
Summary

Intranasal ipratropium bromide effectively reduces watery nasal hypersecretion in perennial rhinitis and the common cold. This parasympatholytic drug offers a safe and prolonged treatment option with rapid onset of action.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Predictors of growth and body composition in HIV-infected children beginning or changing antiretroviral therapy.

HIV medicine·2010
Same author

Methods of haemostasis in tonsillectomy assessed by pain scores and consultation rates. The Roskilde County Tonsillectomy Study.

Acta oto-laryngologica. Supplementum·2000
Same author

Tonsillectomy: assessment of quality by consultation rate after discharge.

The Journal of laryngology and otology·1999
Same author

Efficacy of an aqueous and a powder formulation of nasal budesonide compared in patients with nasal polyps.

American journal of rhinology·1998
Same author

A phase I/II evaluation of oral L-2-oxothiazolidine-4-carboxylic acid in asymptomatic patients infected with human immunodeficiency virus.

Journal of clinical pharmacology·1998
Same author

Common cold and high-dose ipratropium bromide: use of anticholinergic medication as an indicator of reflex-mediated hypersecretion.

Rhinology·1997

Area of Science:

  • Pharmacology
  • Otorhinolaryngology (ENT)
  • Allergy and Immunology

Background:

  • Current treatments for perennial rhinitis and the common cold, particularly watery nasal hypersecretion, remain suboptimal.
  • Nasal glands are innervated by parasympathetic nerves, suggesting a potential therapeutic target.

Purpose of the Study:

  • To investigate the efficacy and safety of intranasal ipratropium bromide for treating watery nasal hypersecretion.
  • To determine the optimal dosage and duration of action for intranasal ipratropium bromide.

Main Methods:

  • Laboratory studies in normal subjects to assess effect, dosage, and duration of intranasal ipratropium bromide.
  • Placebo-controlled clinical short-term study in patients with perennial rhinitis.
  • Open long-term study in patients with perennial rhinitis.
  • Clinical trial in patients with the common cold.

Main Results:

  • Intranasal ipratropium bromide demonstrated significant inhibition of nasal gland secretion for over 6 hours in laboratory studies, with no adverse effects.
  • Effective reduction in watery hypersecretion was observed across all patient groups (perennial rhinitis and common cold).
  • Ipratropium bromide specifically inhibits reflex-induced watery secretion, without affecting basal secretion rates; action is rapid and prolonged.

Conclusions:

  • Intranasal ipratropium bromide is a safe and effective treatment for watery nasal hypersecretion associated with perennial rhinitis and the common cold.
  • The drug offers a rapid onset and prolonged duration of action, with potential for long-term therapeutic or even curative effects in some patients.

Related Experiment Videos